Skip to content

D&A at other companies

Zoetis logo
ZoetisZTS
$119M0.0%
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$172M+6.8%
Neogen logo
NeogenNEOG
$28.92M-1.5%
Balchem logo
BalchemBCPC
$12.49M+13.4%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$6.87M+13.6%
Amgen logo
AmgenAMGN
$1.12B-19.5%

Segments

By segment

See full
Mineral Nutrition$548K+4.6%
Performance Products$249K-10.1%

Other financials

Income statement

See full
Revenue$383.5M+10.3%
Gross profit$125.7M+20.2%
Operating income$44.7M+33.2%
Net income$24.0M+15.1%
EPS (diluted)$0.59+15.7%

Balance sheet

See full
Cash & equivalents$54.9M-9.0%
Total debt$32.3M+27.8%
Total equity$361.8M+36.0%
Total assets$1.4B+9.7%

Cash flow

See full
Operating cash flow$16.2M-62.4%
CapEx$15.3M+97.7%
Free cash flow$890.0K-97.5%

Valuation

See full
Market cap$1.27B+31.4%
Enterprise value$1.25B+33.9%
P/E13.4×-17.1×
P/S0.9×0.0×

Profitability

See full
Gross margin32.5%+0.9pp
Operating margin12%+4.0pp
Net margin6.3%+3.7pp
FCF margin0.9%-3.3pp

Returns & leverage

See full
Return on equity30.3%+18.5pp
Debt / equity0.1×0.0×
Current ratio3.2×+0.3×

Where this comes from

Reported directly by Phibro Animal Health in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phibro Animal Health's D&A?
Phibro Animal Health (PAHC) reported D&A of $12.45M in Q1 2026.
How has Phibro Animal Health's D&A changed year-over-year?
Phibro Animal Health's D&A decreased by 1.3% year-over-year, from $12.62M to $12.45M.
What is the long-term trend for Phibro Animal Health's D&A?
Over 4 years (2021 to 2025), Phibro Animal Health's D&A has grown at a 9.4% compound annual growth rate (CAGR), from $31.89M to $45.61M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.